Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0289902 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Imani Bijou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Mantle cell lymphoma (MCL) has a poor prognosis and high relapse rates despite current therapies, necessitating novel treatment regimens. Inhibition of SRC-3 show effectiveness in vivo and in vitro in other B cell lymphomas. Additionally, previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin’s lymphoma patients, suggesting SRC-3 may play a role in the progression of B cell lymphoma. This study aimed to investigate novel SRC-3 inhibitors, SI-10 and SI-12, in mantle cell lymphoma. The cytotoxic effects of SI-10 and SI-12 were evaluated in vitro and demonstrated dose-dependent cytotoxicity in a panel of MCL cell lines. The in vivo efficacy of SI-10 was confirmed in two ibrutinib-resistant models: an immunocompetent disseminated A20 mouse model of B-cell lymphoma and a human PDX model of MCL. Notably, SI-10 treatment also resulted in a significant extension of survival in vivo with low toxicity in both ibrutinib-resistant murine models. We have investigated SI-10 as a novel anti-lymphoma compound via the inhibition of SRC-3 activity. These findings indicate that targeting SRC-3 should be investigated in combination with current clinical therapeutics as a novel strategy to expand the therapeutic index and to improve lymphoma outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, United States of America.
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
- Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, United States of America.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America.
ORCID-Profile: Jin Wang
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- National Cancer Institute
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Bijou, I., Liu, Y., Lu, D., Chen, J., Sloan, S., Alinari, L., Lonard, D. M., O'Malley, B. W., Wang, M., & Wang, J. (2024). Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0289902
Vancouver
Bijou I, Liu Y, Lu D, Chen J, Sloan S, Alinari L, et al. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0289902
BibTeX
@article{Bijou2024,
author = {Bijou, Imani and Liu, Yang and Lu, Dong and Chen, Jianwei and Sloan, Shelby and Alinari, Lapo and Lonard, David M and O'Malley, Bert W and Wang, Michael and Wang, Jin},
title = {Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0289902}
}
EUVIMED